Clinical Trial

A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan

Completed
View on ClinicalTrials.gov →
Summary
The aim of this study was to describe the patient profile and treatment patterns of adult melanoma patients that were treated with either dabrafenib and trametinib (Dab+Tram) or encorafenib and binimetinib (Enco+Bini) between 01 January 2012 and 30 November 2021 in Japan.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-11.
Trial Details
NCT Number NCT07649252
Lead Sponsor Novartis Pharmaceuticals
Conditions Melanoma
Enrollment 82 participants
Start Date 2022-08-01
Primary Completion 2022-11-20 (estimated)
Study Completion 2022-11-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-17